E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Relapsed or refractory Hodgkin’s lymphoma |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020328 |
E.1.2 | Term | Hodgkin's lymphoma |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this trial is to determine the best overall objective response rate (ORR) based on IWG criteria (20) of 4SC-201 in patients with refractory or relapsed HL |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this trial are: • to investigate the safety and tolerability of repeated oral doses of 4SC-201 • to assess overall survival (OS) in patients treated with repeated oral doses of 4SC-201 • to determine progression free survival (PFS) in patients treated with repeated oral doses of 4SC-201, including radiological and symptomatic progression • to determine time to progression (TTP) in patients treated with repeated oral doses of 4SC-201 including objective and symptomatic progression • to determine duration of response (DOR) in patients treated with repeated oral doses of 4SC-201 • to assess the pharmacokinetics of 4SC-201 after oral dosing
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients must have histological or cytological evidence of Hodgkin’s lymphoma (all subtypes are acceptable). Patients must have relapsed HL after second or subsequent-line therapy or have a refractory disease defined as non-CR after or PD during first-line therapy and PD following second-line (salvage) therapy. Patients may have also undergone high-dose chemotherapy with autologous stem cell transplantation at least 12 weeks prior to study entry. Patients must have measurable anatomical disease present on CT scan Patients must be > 18 years of age Patients must have an ECOG Performance Score of 0, 1 or 2 (Appendix A) Patients must have a life expectancy of at least 12 weeks Patients or their legal representatives must be able to comprehend and provide written informed consent Patients must have adequate bone marrow reserve as evidenced by: Absolute neutrophil count (ANC) > 1,500/µl Platelet count > 75,000/µl Patients must have adequate renal function as evidenced by a serum creatinine <2.0 mg/dl Patients must have adequate hepatic function as evidenced by a serum bilirubin < 2.0 mg/dl and serum asparatate aminotransferase (AST) and alanine aminotransferase (ALT) levels < 3X the ULN for the reference lab (< 5X the ULN if there is known to be hepatic involvement by HL) Patients must be fully recovered from the effects of any prior therapy for HL. Women of childbearing potential must have a negative urine or serum pregnancy test (a women is considered to be NOT of childbearing potential if she has undergone bilateral oophorectomy or if she has been menopausal without a menstrual period for 12 consecutive months) Women of childbearing potential as well as fertile men and their partners must agree to either abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of study medication (an effective form of contraception is an oral contraceptive or a double barrier method, such as condom and diaphragm) Men with partners of childbearing potential are requested to use barrier contraception in addition to having their partner use another method of contraception during the trial and until at least 3 months following the last administration of the study medication. Male patients will also be advised to abstain from sexual intercourse with pregnant or lactating women, or to use condoms.
|
|
E.4 | Principal exclusion criteria |
Patients who have received previous treatment with an HDAC inhibitor Patients who have undergone allogeneic hematopoietic stem cell transplantation Patients with known or suspected involvement of the CNS by HL Any gastrointestinal disorder that could interfere with the absorption of 4SC-201, such as active ulcerative colitis, Crohn’s disease, diabetic gastroparesis, or other syndromes characterized by malabsorption Therapy with agents known to prolong the QT interval (Appendix E) Patients with a history of other malignancies unless having undergone definitive treatment more than 5 years prior to entry into the study and without evidence of recurrent malignant disease, excluding patients with basal cell carcinoma of the skin; superficial carcinoma of the bladder; carcinoma of the prostate with a current PSA < 0.1 ng/ml; or cervical intraepithelial neoplasia. Patients with a history of significant cardiovascular, neurological, endocrine, gastrointestinal, respiratory or inflammatory illness that could preclude their participation in the trial, pose an undue medical hazard or interfere with the interpretation of the trial results, including, but not limited to, patients with congestive heart failure (NYHA Class 3 or 4); unstable angina; cardiac arrhythmia; recent (within the preceding 6 months) myocardial infarction or stroke; hypertension requiring > 2 medications for adequate control; diabetes mellitus with > 2 episodes of ketoacidosis in the preceding 12 months. Patients with any other medical, psychiatric or social condition, which in the opinion of the investigator would preclude participation in the trial, pose an undue medical hazard, interfere with the conduct of the trial or interfere with interpretation of the trial results Patients with a history of hypersensitivity reactions to any of the components of 4SC-201 Women who are pregnant or lactating or who are planning on becoming pregnant during the trial or for 90 days after completion of the trial Patients who have received an investigational therapy within 4 weeks of signing the informed consent for the current study Patients with a confirmed QTcF > 450 msec Patients with a history of, who were treated for, or who are suspected of having, hepatitis B, hepatitis C or HIV. Patients suspected of having any of these conditions should undergo appropriate evaluations prior to being enrolled in the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The objective response rate (ORR) will be defined as the best response over the course of a patient’s participation in the trial. For the purposes of this trial, objective response will be a complete response or partial response based on anatomical imaging according to the International Working Group (IWG) criteria, or stable anatomical disease with improvement in functional (PET) imaging. The ORR and the exact 95% confidence interval will be presented. The ORR will be evaluated on the efficacy population. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will conclude when the last patient remaining in the study completes 12 months of therapy, expires, develops progressive neoplastic disease, or discontinues treatment for any other reason. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |